Abstracts Archive - Page 223 of 2607 - ACR Meeting Abstracts

Abstract Number: 2610 • ACR Convergence 2024
Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial
Johannes Knitza¹, Johanna Mucke², Manuel Grahammer³, Sebastian Kuhn¹, Nicolas Vuillerme⁴, Felix Muehlensiepen⁵, Gerhard Krönke⁶, Georg Schett⁷, Ann-Christin Pecher⁸ and Martin Krusche⁹, and the TELERA Study Group, ¹Institute for Digital Medicine, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany, Marburg, Germany, ²Heinrich-Heine-University, Duesseldorf, Germany, ³ABATON, Berlin, Germany, ⁴AGEIS, Université Grenoble Alpes, 38000 Grenoble, France, Grenoble, France, ⁵Center for Health Services Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany, Berlin, Germany, ⁶Rheumatology, Charité, Berlin, Germany, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Interdisciplinary Center of Rheumatic Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany, Tübingen, Germany, ⁹III Department of Medicine, Division of Rheumatology and Systemic Inflammatory Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany
Background/Purpose: Access to rheumatology care is becoming increasingly limited, necessitating a re-evaluation of patient pathways. The objective of this study was to evaluate a new…
Abstract Number: 2485 • ACR Convergence 2024
Orbital Pseudotumor in Granulomatosis with Polyangiitis. Interim Analysis of Clinical Outcomes from a European Collaborative Observational Study
Luca Moroni¹, Gabriele Gallina², Marco Lanzillotta², Sara Maggioni², Giovanni Benanti², Adriana Cariddi², Paolo Delvino³, Sara Monti⁴, Alessandra Milanesi⁵, Filippo Fagni⁶, Marco Fornaro⁷, Camille Taille⁸, Elena Treppo⁹, Grégory Pugnet¹⁰, Emanuele Chiara¹¹, Roberto Padoan¹², Luca Iorio¹³, Federica Davanzo¹², Eleonora Fiorin¹⁴, Alvise Berti¹⁵, Roberto Bortolotti¹⁶, Sergey Moiseev¹⁷, Pavel Novikov¹⁷, Askin Ates¹⁸, Ahmet Omma¹⁹, Tahir Saygin Ogut²⁰, Gozde Sevgi Kart-Bayram²¹, Tuba Demirci²², Riza Can Kardas²³, Ömer Karadağ²¹, Marco Matucci-Cerinic²⁴ and Lorenzo Dagna²⁵, ¹IRCCS San Raffaele Scientific Institute, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milano, Italy, Milano, Italy, ²IRCCS Ospedale San Raffaele, Milano, Italy, ³University of Milano-Bicocca, Milan, Milan, Italy, ⁴IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁵Unit of Rheumatology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, ⁶Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁷Università di Bari, Bari, Italy, ⁸Bichat Hospital, Paris, France, ⁹Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ¹⁰Toulouse Rangueil University Hospital, Toulouse, France, ¹¹Ospedale Careggi, Firenze, Italy, ¹²Azienda Ospedaliera-Universitaria di Padova, Padova, Italy, ¹³Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy, ¹⁴Azienda Ospedaliera-Universitaria di Padova, Padova, ¹⁵Rheumatology Unit Santa Chiara Hospital of Trento, Trento, Italy, ¹⁶Rheumatology Unit Santa Chiara Hospital of Trento, Trento, ¹⁷Sechenov First Moscow State Medical University, Moscow, Russia, ¹⁸Ankara University, Ankara, Turkey, ¹⁹Ankara Bilkent City Hospital, Ankara, Turkey, ²⁰Akdeniz University, Antalya, Turkey, ²¹Hacettepe University School of Medicine, Ankara, Turkey, ²²Dokuz Eylül University, Izmir, Turkey, ²³Gazi University, Ankara, Turkey, ²⁴University San Raffaele Milano, Milano, Milan, Italy, ²⁵Ospedale San Raffaele, Milano, Italy
Background/Purpose: Orbital Pseudotumor (OPT) is a rare organ-threatening manifestation of Granulomatosis with Polyangiitis (GPA), with severe prognosis and historically refractory to most treatments. This is…
Abstract Number: 2694 • ACR Convergence 2024
Associations Between Immune Checkpoint Molecules and Nasal Microbiome in ANCA-associated Vasculitis
Yoichi Nakayama¹, Mirei Shirakashi², Erika Furukawa³, Chikako Endo⁴, Tsuneo Sasai⁵, Yuya Tabuchi⁴, Ryosuke Hiwa⁵, Hideaki Tsuji⁵, Koji Kitagori⁶, Shuji Akizuki⁷, Ran Nakashima⁵, Kosaku Murakami³, Hajime Yoshifuji⁵ and Akio Morinobu⁸, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Hirakata-shi, Osaka-fu, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ³Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁶Occupational Welfare Division, Agency for Health, Safety and Environment, Kyoto University,, Kyoto, Kyoto, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Among patients with ANCA-associated vasculitis (AAV), several exhibit sinonasal involvement, especially in granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA). A recent…
Abstract Number: PP04 • ACR Convergence 2024
Involving Pediatric Patients in Their Own Care
Whitney LaBar, Lupus and Allied Diseases Association, Pleasanton, CA
Background/Purpose: When I was 14, I was diagnosed with thrombocytopenia, which led to more testing and a diagnosis of systemic lupus erythematosus (SLE). As a…
Abstract Number: PP05 • ACR Convergence 2024
Reunion with Forgotten Relationships and Memories
Noriko Okochi¹, Eiji Oishi², Kaoru Mitsuyama³, Emi Sorimachi³, Shiho Bando⁴, Yuka Hirama⁵, Nobuyuki Yajima⁶ and Masaaki Mori⁷, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan, ³Institute of Neuropsychiatry, Tokyo, Tokyo, Japan, ⁴Ota-ku Children and Families Support Center, Ota-ku, Tokyo, Japan, ⁵Asada Ladies Clinic, Shinagawa, Japan, Tokyo, Japan, ⁶Showa-Universtiy of Medicine, Tokyo, Japan, ⁷Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Paediatric rheumatic diseases are complex experiences for children. For children whose language skills are still undeveloped, it is difficult for them to put their…
Abstract Number: 2669 • ACR Convergence 2024
Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies
Hannah Bulgart¹, Kassidy Banford², Shane Bruckner³, Kevin McElhanon², Nicholas Young¹, Brian Paleo², Eric Beck², Rohit Aggarwal⁴, Chester Oddis⁵, Braden Zeno⁶, Wael Jarjour⁷ and Noah Weisleder³, ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University, Columbus, ³Ohio State University, Columbus, OH, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Ohio State University, upper arlington, OH, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Idiopathic immune myopathies (IIMs) are a group of autoimmune diseases that produce chronic inflammation and degeneration of skeletal muscle structure and function. One process…
Abstract Number: 2613 • ACR Convergence 2024
Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study
Gregory McDermott¹, Ritu Gill², Suzanne Byrne³, Staci Gagne³, Emily Kowalski³, Xiaosong Wang⁴, Grace Qian⁴, Katarina Bade³, Kevin Mueller³, Alene Saavedra³, Kathleen Vanni⁴, Caleb Bolden⁵, Naomi Patel⁵, Krishan Guzzo³, Marcy Bolster⁵, Shruthi Srivatsan⁵, Pierre-Antoine Juge⁶, Tracy J Doyle⁷, Zachary Wallace⁸ and Jeffrey Sparks⁹, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁷Brigham and Women's Hospital, West Roxbury, MA, ⁸Massachusetts General Hospital, Newton, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA is associated with several forms of parenchymal lung disease, including interstitial lung disease (ILD), bronchiectasis, and emphysema. Acute COVID-19 and other respiratory viruses…
Abstract Number: PP15 • ACR Convergence 2024
Breathing Mindfully and How to Control Anxiety in Lupus Patients
Amanda Greene, Lupus Research Alliance, Los Angeles, CA
Background/Purpose: For over four decades, Systemic Lupus Erythematosus has impacted my Quality of Life.. I was diagnosed in 1983- my entire life was changed. I…
Abstract Number: PP16 • ACR Convergence 2024
Utilization of My Knee Notes for Enhanced Healthcare Management
Tien Sydnor-Campbell, Medically Retired, Philadelphia, PA
Background/Purpose: Living with chronic knee issues for 40 years has been incredibly challenging. My knee pain began as early as 6th grade but got overlooked…
Abstract Number: 2624 • ACR Convergence 2024
Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jessica Neely¹, Peter Shrader², Stacey Tarvin³, Kaveh Ardalan⁴, Susan Shenoi⁵, Adam Huber⁶, Susan Kim⁷ and Hanna Kim⁸, and for the CARRA Registry Investigators, ¹UCSF, San Francisco, CA, ²Duke Clinical Research Institute, Durham, NC, ³Indiana University School of Medicine, Indianapolis, IN, ⁴Duke University School of Medicine, Durham, NC, ⁵Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷University of California, San Francisco, CA, ⁸National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: While remission off medication is the goal in JDM, timely achievement of clinically inactive disease (CID) is an important interim outcome. Data from the…
Abstract Number: 2518 • ACR Convergence 2024
Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype
Yesim Ozguler¹, Olivier Manches², Didar Ucar³, Ziyan Lin², Alireza Khodadadi-Jamayran², Aristotelis Tsirigos², Gulen Hatemi¹ and Johannes Nowatzky⁴, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²NYU Grossman School of Medicine, New York, NY, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: The immune landscape of Behçet’s disease (BD) remains ill-defined, lacking a unifying picture, precise disease phenotype-endotype correlations, and an understanding of immunity at target…
Abstract Number: PP02 • ACR Convergence 2024
Living Well with a Rare Rheumatic Disease – Becoming a “Precision” Patient on the Horizon of Precision Medicine
Ida Hakkarinen, self, Greenbelt, MD
Background/Purpose: My journey with a rare, chronic, relapsing rheumatic disease began in November 2010 with a variety of seemingly unrelated symptoms: migrating joint pain, night…
Abstract Number: 2643 • ACR Convergence 2024
Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis
Kristina Clark¹, Corrado Campochiaro², Emma Derrett-Smith³, Voon Ong⁴, Christopher Buckley⁵ and Christopher Denton⁶, ¹University of Oxford, Oxford, United Kingdom, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³University College London Division of Medicine, Birmingham, United Kingdom, ⁴University College London, London, England, United Kingdom, ⁵Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁶University College London, Northwood, United Kingdom
Background/Purpose: Myofibroblasts are key cells in the pathogenesis of systemic sclerosis (SSc). TGFβ is a key growth factor driving myofibroblast formation in SSc. The main…
Abstract Number: 2527 • ACR Convergence 2024
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
Jacques-Eric Gottenberg¹, Kathy Sivils², Kim Campbell³, Jada Idokogi³, Kim Lo³, Sophia G. Liva³, Jonathan Shelton⁴, Harman Dhatt⁵, Jonathan J. Hubbard³ and Ghaith Noaiseh⁶, ¹Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ²Johnson & Johnson Innovative Medicine, Edmond, OK, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Janssen Scientific Affairs, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, USA, Raritan, NJ, ⁶University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of specific autoantibodies (AAb) and lymphocytic infiltration of exocrine glandular tissues.…
Abstract Number: 2538 • ACR Convergence 2024
HLA-DRB1 Rheumatoid Arthritis (RA) Risk Alleles Preferentially Select TRBJ2-3-containing CD4 T Cells in RA Patients
Amit Lakhanpal¹, Kazuyoshi Ishigaki², Anvita Singaraju¹, Alejandro Kochen³, Miriam Fein¹, Soumya Raychaudhuri⁴ and Laura Donlin¹, ¹Hospital for Special Surgery, New York, NY, ²Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan; Keio University Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q);; Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Bunkyo-ku, Tokyo, Japan, ³Yale School of Medicine, New Haven, CT, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The largest genetic risk factor for RA localizes to the MHC Class II HLA-DRB1 gene, which encodes the machinery for antigen presentation to CD4…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].